MENY

Gällande vårdprogram analcancer

Fastställt av Regionala cancercentrum i samverkan 2017-12-07.

22. Referenser

1.Wendell-Smith CP. Anorectal nomenclature: fundamental terminology. Diseases of the colon and rectum. 2000;43(10):1349-58.

2.Fenger C. The anal transitional zone. Acta pathologica, microbiologica, et immunologica Scandinavica Supplement. 1987;289:1-42.

3.Dujovny N, Quiros RM, Saclarides TJ. Anorectal anatomy and embryology. Surgical oncology clinics of North America. 2004;13(2):277-93.

4.Franceschi S, De Vuyst H. Human papillomavirus vaccines and anal carcinoma. Current opinion in HIV and AIDS. 2009;4(1):57-63.

5.Salit IE, Lytwyn A, Raboud J, Sano M, Chong S, Diong C, et al. The role of cytology (Pap tests) and human papillomavirus testing in anal cancer screening. AIDS (London, England). 2010;24(9):1307-13.

6.Saboo SS, Zukotynski K, Shinagare AB, Krajewski KM, Ramaiya N. Anal carcinoma: FDG PET/CT in staging, response evaluation, and follow-up. Abdominal imaging. 2013;38(4):728-35.

7.Glynne-Jones R, Northover JM, Cervantes A. Anal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2010;21 Suppl 5:v87-92.

8.Jones M, Hruby G, Solomon M, Rutherford N, Martin J. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Annals of surgical oncology. 2015;22(11):3574-81.

9.Agarwal A, Marcus C, Xiao J, Nene P, Kachnic LA, Subramaniam RM. FDG PET/CT in the management of colorectal and anal cancers. AJR American journal of roentgenology. 2014;203(5):1109-19.

10.Bhuva NJ, Glynne-Jones R, Sonoda L, Wong WL, Harrison MK. To PET or not to PET? That is the question. Staging in anal cancer. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 2012;23(8):2078-82.

11.Caldarella C, Annunziata S, Treglia G, Sadeghi R, Ayati N, Giovanella L. Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis. TheScientificWorldJournal. 2014;2014:196068.

12.Braendengen M, Hansson K, Radu C, Siegbahn A, Jacobsson H, Glimelius B. Delineation of gross tumor volume (GTV) for radiation treatment planning of locally advanced rectal cancer using information from MRI or FDG-PET/CT: a prospective study. International journal of radiation oncology, biology, physics. 2011;81(4):e439-45.

13.Anderson C, Koshy M, Staley C, Esiashvili N, Ghavidel S, Fowler Z, et al. PET-CT fusion in radiation management of patients with anorectal tumors. International journal of radiation oncology, biology, physics. 2007;69(1):155-62.

14.Engstrom PF, Arnoletti JP, Benson AB, 3rd, Berlin JD, Berry JM, Chen YJ, et al. NCCN clinical practice guidelines in oncology. Anal carcinoma. Journal of the National Comprehensive Cancer Network : JNCCN. 2010;8(1):106-20.

15.Avallone A, Aloj L, Caraco C, Delrio P, Pecori B, Tatangelo F, et al. Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. European journal of nuclear medicine and molecular imaging. 2012;39(12):1848-57.

16.Cascini GL, Avallone A, Delrio P, Guida C, Tatangelo F, Marone P, et al. 18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2006;47(8):1241-8.

17.Mistrangelo M, Pelosi E, Bello M, Ricardi U, Milanesi E, Cassoni P, et al. Role of positron emission tomography-computed tomography in the management of anal cancer. International journal of radiation oncology, biology, physics. 2012;84(1):66-72.

18.Vercellino L, Montravers F, de Parades V, Huchet V, Kerrou K, Bauer P, et al. Impact of FDG PET/CT in the staging and the follow-up of anal carcinoma. International journal of colorectal disease. 2011;26(2):201-10.

19.Goh V, Gollub FK, Liaw J, Wellsted D, Przybytniak I, Padhani AR, et al. Magnetic resonance imaging assessment of squamous cell carcinoma of the anal canal before and after chemoradiation: can MRI predict for eventual clinical outcome? International journal of radiation oncology, biology, physics. 2010;78(3):715-21.

20.Kochhar R, Renehan AG, Mullan D, Chakrabarty B, Saunders MP, Carrington BM. The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer. European radiology. 2017;27(2):607-17.

21.NCCN Guidelines Anal Carcinoma version 2 2015 [Available from: http://www.tri-kobe.org/nccn/guideline/colorectal/english/anal.pdf.

22.Brierley JD GM, Wittekind C. TNM classification of malignant tumours. 8th edition ed: Wiley-Blackwell 2016.

23.Leon O, Guren M, Hagberg O, Glimelius B, Dahl O, Havsteen H, et al. Anal carcinoma - Survival and recurrence in a large cohort of patients treated according to Nordic guidelines. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2014;113(3):352-8.

24.Bosman FT, Carneiro, F., Hruban, R.H., Theise, N.D. WHO Classification of Tumours of the Digestive System, Fourth Edition 2010.

25.Brierley JD, Gospodarowicz, M.K., Wittekind, C. TNM Classification of Malignant Tumours, 7th Edition: November 2009, Wiley-Blackwell

2009.

26.Walts AE, Lechago J, Bose S. P16 and Ki67 immunostaining is a useful adjunct in the assessment of biopsies for HPV-associated anal intraepithelial neoplasia. The American journal of surgical pathology. 2006;30(7):795-801.

27.Gilbert DC, Williams A, Allan K, Stokoe J, Jackson T, Linsdall S, et al. p16INK4A, p53, EGFR expression and KRAS mutation status in squamous cell cancers of the anus: correlation with outcomes following chemo-radiotherapy. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;109(1):146-51.

28.Mai S, Welzel G, Ottstadt M, Lohr F, Severa S, Prigge ES, et al. Prognostic Relevance of HPV Infection and p16 Overexpression in Squamous Cell Anal Cancer. International journal of radiation oncology, biology, physics. 2015;93(4):819-27.

29.Serup-Hansen E, Linnemann D, Skovrider-Ruminski W, Hogdall E, Geertsen PF, Havsteen H. Human papillomavirus genotyping and p16 expression as prognostic factors for patients with American Joint Committee on Cancer stages I to III carcinoma of the anal canal. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014;32(17):1812-7.

30.Nigro ND, Seydel HG, Considine B, Vaitkevicius VK, Leichman L, Kinzie JJ. Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer. 1983;51(10):1826-9.

31.Nigro ND, Vaitkevicius VK, Considine B, Jr. Combined therapy for cancer of the anal canal: a preliminary report. Diseases of the colon and rectum. 1974;17(3):354-6.

32.Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1997;15(5):2040-9.

33.Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet (London, England). 1996;348(9034):1049-54.

34.Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1996;14(9):2527-39.

35.Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr., et al. Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. Jama. 2008;299(16):1914-21.

36.James RD, Glynne-Jones R, Meadows HM, Cunningham D, Myint AS, Saunders MP, et al. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 x 2 factorial trial. The Lancet Oncology. 2013;14(6):516-24.

37.Peiffert D, Tournier-Rangeard L, Gerard JP, Lemanski C, Francois E, Giovannini M, et al. Induction chemotherapy and dose intensification of the radiation boost in locally advanced anal canal carcinoma: final analysis of the randomized UNICANCER ACCORD 03 trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012;30(16):1941-8.

38.Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr., et al. Prognostic factors derived from a prospective database dictate clinical biology of anal cancer: the intergroup trial (RTOG 98-11). Cancer. 2010;116(17):4007-13.

39.Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB, 3rd, Thomas CR, Jr., et al. US intergroup anal carcinoma trial: tumor diameter predicts for colostomy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(7):1116-21.

40.Bentzen AG, Guren MG, Wanderas EH, Frykholm G, Tveit KM, Wilsgaard T, et al. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort. International journal of radiation oncology, biology, physics. 2012;83(2):e173-80.

41.Lund JA, Wibe A, Sundstrom SH, Haaverstad R, Kaasa S, Myrvold HE. Anal carcinoma in mid-Norway 1970-2000. Acta oncologica (Stockholm, Sweden). 2007;46(7):1019-26.

42.Hatfield P, Cooper R, Sebag-Montefiore D. Involved-field, low-dose chemoradiotherapy for early-stage anal carcinoma. International journal of radiation oncology, biology, physics. 2008;70(2):419-24.

43.Muirhead R. National guidance for IMRT in Anal Cancer 2016 [updated 18/04/2016. 3:[Available from: http://analimrtguidance.co.uk/national-anal-imrt-guidance-v3.pdf.

44.Das P, Bhatia S, Eng C, Ajani JA, Skibber JM, Rodriguez-Bigas MA, et al. Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. International journal of radiation oncology, biology, physics. 2007;68(3):794-800.

45.Wright JL, Patil SM, Temple LK, Minsky BD, Saltz LB, Goodman KA. Squamous cell carcinoma of the anal canal: patterns and predictors of failure and implications for intensity-modulated radiation treatment planning. International journal of radiation oncology, biology, physics. 2010;78(4):1064-72.

46.Lepinoy A, Lescut N, Puyraveau M, Caubet M, Boustani J, Lakkis Z, et al. Evaluation of a 36 Gy elective node irradiation dose in anal cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2015;116(2):197-201.

47.Henkenberens C, Meinecke D, Michael S, Bremer M, Christiansen H. Reduced radiation dose for elective nodal irradiation in node-negative anal cancer: back to the roots? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft  [et al]. 2015;191(11):845-54.

48.Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy--results of a multicentric randomized German trial in advanced head-and-neck cancer. International journal of radiation oncology, biology, physics. 2001;50(5):1161-71.

49.Sheikh H, Colaco R, Lorigan P, Blackhall F, Califano R, Ashcroft L, et al. Use of G-CSF during concurrent chemotherapy and thoracic radiotherapy in patients with limited-stage small-cell lung cancer safety data from a phase II trial. Lung cancer (Amsterdam, Netherlands). 2011;74(1):75-9.

50.Pape H, Orth K, Heese A, Heyll A, Kobbe G, Schmitt G, et al. G-CSF during large field radiotherapy reduces bone marrow recovery capacity. European journal of medical research. 2006;11(8):322-8.

51.Charnley N, Choudhury A, Chesser P, Cooper RA, Sebag-Montefiore D. Effective treatment of anal cancer in the elderly with low-dose chemoradiotherapy. British journal of cancer. 2005;92(7):1221-5.

52.Glynne-Jones R, Meadows H, Wan S, Gollins S, Leslie M, Levine E, et al. EXTRA--a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer. International journal of radiation oncology, biology, physics. 2008;72(1):119-26.

53.Meulendijks D, Dewit L, Tomasoa NB, van Tinteren H, Beijnen JH, Schellens JH, et al. Chemoradiotherapy with capecitabine for locally advanced anal carcinoma: an alternative treatment option. British journal of cancer. 2014;111(9):1726-33.

54.Peixoto RD, Wan DD, Schellenberg D, Lim HJ. A comparison between 5-fluorouracil/mitomycin and capecitabine/mitomycin in combination with radiation for anal cancer. Journal of gastrointestinal oncology. 2016;7(4):665-72.

55.Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, et al. Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). European journal of cancer (Oxford, England : 1990). 2009;45(16):2782-91.

56.Ng M, Leong T, Chander S, Chu J, Kneebone A, Carroll S, et al. Australasian Gastrointestinal Trials Group (AGITG) contouring atlas and planning guidelines for intensity-modulated radiotherapy in anal cancer. International journal of radiation oncology, biology, physics. 2012;83(5):1455-62.

57.Bentzen SM, Constine LS, Deasy JO, Eisbruch A, Jackson A, Marks LB, et al. Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC): an introduction to the scientific issues. International journal of radiation oncology, biology, physics. 2010;76(3 Suppl):S3-9.

58.Hannoun-Levi JM, Ortholan C, Resbeut M, Teissier E, Ronchin P, Cowen D, et al. High-dose split-course radiation therapy for anal cancer: outcome analysis regarding the boost strategy (CORS-03 study). International journal of radiation oncology, biology, physics. 2011;80(3):712-20.

59.Roed H, Engelholm SA, Svendsen LB, Rosendal F, Olsen KJ. Pulsed dose rate (PDR) brachytherapy of anal carcinoma. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1996;41(2):131-4.

60.Bruna A, Gastelblum P, Thomas L, Chapet O, Bollet MA, Ardiet JM, et al. Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2006;79(1):75-9.

61.Niehoff P, Kovacs G. HDR brachytherapy for anal cancer. Journal of gastrointestinal oncology. 2014;5(3):218-22.

62.Chan RJ, Larsen E, Chan P. Re-examining the evidence in radiation dermatitis management literature: an overview and a critical appraisal of systematic reviews. International journal of radiation oncology, biology, physics. 2012;84(3):e357-62.

63.Feight D, Baney T, Bruce S, McQuestion M. Putting evidence into practice. Clinical journal of oncology nursing. 2011;15(5):481-92.

64.Hollinworth H, Mann L. Managing acute skin reactions to radiotherapy treatment. Nursing standard (Royal College of Nursing (Great Britain) : 1987). 2010;24(24):53-4, 6, 8 passim.

65.Kumar S, Juresic E, Barton M, Shafiq J. Management of skin toxicity during radiation therapy: a review of the evidence. Journal of medical imaging and radiation oncology. 2010;54(3):264-79.

66.MacBride SK, Wells ME, Hornsby C, Sharp L, Finnila K, Downie L. A case study to evaluate a new soft silicone dressing, Mepilex Lite, for patients with radiation skin reactions. Cancer nursing. 2008;31(1):E8-14.

67.Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). International journal of radiation oncology, biology, physics. 1995;31(5):1341-6.

68.Läkemedelsboken  [Available from: http://lakemedelsboken.se/kapitel/smarta/smarta_och_smartbehandling.html.

69.Kreftsykepleie/under redaktion av Anne Marie Reitan och Tore Kr. Schölberg. Oslo: Akribe; 2010.

70.Vårdhandboken  [Available from: http://www.vardhandboken.se/.

71.Nationellt vårdprogram tjock- och ändtarmscancer: Regionala cancercentrum i Samverkan;  [Available from: http://www.cancercentrum.se/samverkan/cancerdiagnoser/tjock--och-andtarm/vardprogram/.

72.Glynne-Jones R, Nilsson PJ, Aschele C, Goh V, Peiffert D, Cervantes A, et al. Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. 2014;40(10):1165-76.

73.Renehan AG, O'Dwyer ST. Management of local disease relapse. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2011;13 Suppl 1:44-52.

74.Simpson JA, Scholefield JH. Diagnosis and management of anal intraepithelial neoplasia and anal cancer. BMJ (Clinical research ed). 2011;343:d6818.

75.Abbasakoor F, Boulos PB. Anal intraepithelial neoplasia. The British journal of surgery. 2005;92(3):277-90.

76.Bentzen AG, Balteskard L, Wanderas EH, Frykholm G, Wilsgaard T, Dahl O, et al. Impaired health-related quality of life after chemoradiotherapy for anal cancer: late effects in a national cohort of 128 survivors. Acta oncologica (Stockholm, Sweden). 2013;52(4):736-44.

77.Bentzen AG, Guren MG, Vonen B, Wanderas EH, Frykholm G, Wilsgaard T, et al. Faecal incontinence after chemoradiotherapy in anal cancer survivors: long-term results of a national cohort. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2013;108(1):55-60.

78.Clark MA, Hartley A, Geh JI. Cancer of the anal canal. The Lancet Oncology. 2004;5(3):149-57.

79.Lefevre JH, Parc Y, Kerneis S, Shields C, Touboul E, Chaouat M, et al. Abdomino-perineal resection for anal cancer: impact of a vertical rectus abdominis myocutaneus flap on survival, recurrence, morbidity, and wound healing. Annals of surgery. 2009;250(5):707-11.

80.Sunesen KG, Buntzen S, Tei T, Lindegaard JC, Norgaard M, Laurberg S. Perineal healing and survival after anal cancer salvage surgery: 10-year experience with primary perineal reconstruction using the vertical rectus abdominis myocutaneous (VRAM) flap. Annals of surgical oncology. 2009;16(1):68-77.

81.Branagan G. Staging and management of inguinal nodes. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland. 2011;13 Suppl 1:29-32.

82.Murthy V, Gopinath KS. Reconstruction of groin defects following radical inguinal lymphadenectomy: an evidence based review. Indian journal of surgical oncology. 2012;3(2):130-8.

83.Swan MC, Furniss D, Cassell OC. Surgical management of metastatic inguinal lymphadenopathy. BMJ (Clinical research ed). 2004;329(7477):1272-6.

84.Pawlik TM, Gleisner AL, Bauer TW, Adams RB, Reddy SK, Clary BM, et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Annals of surgical oncology. 2007;14(10):2807-16.

85.Eng C, Chang GJ, You YN, Das P, Rodriguez-Bigas M, Xing Y, et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget. 2014;5(22):11133-42.

86.Dewdney A, Rao S. Metastatic squamous cell carcinoma of the anus: time for a shift in the treatment paradigm? ISRN oncology. 2012;2012:756591.

87.Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D. Carboplatin and paclitaxel treatment is effective in advanced anal cancer. Oncology. 2014;87(2):125-32.

88.Golub DV, Civelek AC, Sharma VR. A regimen of taxol, Ifosfamide, and platinum for recurrent advanced squamous cell cancer of the anal canal. Chemotherapy research and practice. 2011;2011:163736.

89.Rogers JE, Silva NN, Eng C. Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. Journal of gastrointestinal oncology. 2015;6(5):E82-5.

90.Lukan N, Strobel P, Willer A, Kripp M, Dinter D, Mai S, et al. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status. Oncology. 2009;77(5):293-9.

91.Klimant E, Markman M. Management of two cases of recurrent anal carcinoma. Case reports in oncology. 2013;6(3):456-61.

92.Hallemeier CL, You YN, Larson DW, Dozois EJ, Nelson H, Klein KA, et al. Multimodality therapy including salvage surgical resection and intraoperative radiotherapy for patients with squamous-cell carcinoma of the anus with residual or recurrent disease after primary chemoradiotherapy. Diseases of the colon and rectum. 2014;57(4):442-8.

93.Socialdepartementet. SOU 2009:11, En nationell cancerstrategi för framtiden. 2009.

94.Hälso- och sjukvårdslagen (1982:763). In: Socialdepartementet, editor.

95.Insatser för fler kontaktsjuksköterskor inom cancervården. Ännu bättre cancervård - delrapport 8 2012 [Available from: https://www.cancercentrum.se/globalassets/patient-och-narstaende/samverkan/delrapport-8_kontaktsjukskoterskor_1310131.pdf.

96.Fowler C, Kirschner M, Van Kuiken D, Baas L. Promoting self-care through symptom management: a theory-based approach for nurse practitioners. Journal of the American Academy of Nurse Practitioners. 2007;19(5):221-7.

97.Kriterier som ska utmärka ett regionalt cancercentrum (RCC). In: Socialdepartementet, editor. 2011.

98.Kontaktsjukksköterskor i cancervård, en delrapport 2011 [Available from: http://www.ilco.nu/Global/Nyheter%202012/April/Alla%20ska%20ha%20r%c3%a4tt%20till%20kontaktsjuksk%c3%b6terska.pdf.

99.Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013;31(19):2500-10.

100.Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: a new understanding to improve management of symptomatic patients. The Lancet Oncology. 2007;8(11):1007-17.

101.Andreyev HJ, Muls AC, Norton C, Ralph C, Watson L, Shaw C, et al. Guidance: The practical management of the gastrointestinal symptoms of pelvic radiation disease. Frontline gastroenterology. 2015;6(1):53-72.

102.Ehrenpreis ED, Marsh, R de W, Small Jr., W. . Radiation Therapy for Pelvic Malignancy and its Consequences. New York: Springer; 2015.

103.Miles T, Johnson N. Vaginal dilator therapy for women receiving pelvic radiotherapy. The Cochrane database of systematic reviews. 2014(9):Cd007291.

104.Adams E, Boulton MG, Horne A, Rose PW, Durrant L, Collingwood M, et al. The effects of pelvic radiotherapy on cancer survivors: symptom profile, psychological morbidity and quality of life. Clinical oncology (Royal College of Radiologists (Great Britain)). 2014;26(1):10-7.

105.Oh CC, Ko HC, Lee HY, Safdar N, Maki DG, Chlebicki MP. Antibiotic prophylaxis for preventing recurrent cellulitis: a systematic review and meta-analysis. The Journal of infection. 2014;69(1):26-34.

106.Dunberger G, Bergmark K. Nurse-led care for the management of side effects of pelvic radiotherapy: what does it achieve? Current opinion in supportive and palliative care. 2012;6(1):60-8.

107.Thomé B. HM. Perspektiv på onkologisk vård: Studentlitteratur; 2011.